JP2020515589A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515589A5
JP2020515589A5 JP2019553366A JP2019553366A JP2020515589A5 JP 2020515589 A5 JP2020515589 A5 JP 2020515589A5 JP 2019553366 A JP2019553366 A JP 2019553366A JP 2019553366 A JP2019553366 A JP 2019553366A JP 2020515589 A5 JP2020515589 A5 JP 2020515589A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019553366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515589A (ja
JP7196093B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/026134 external-priority patent/WO2018187506A1/en
Publication of JP2020515589A publication Critical patent/JP2020515589A/ja
Publication of JP2020515589A5 publication Critical patent/JP2020515589A5/ja
Application granted granted Critical
Publication of JP7196093B2 publication Critical patent/JP7196093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019553366A 2017-04-05 2018-04-04 Ask1阻害剤化合物とその使用 Active JP7196093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762482085P 2017-04-05 2017-04-05
US62/482,085 2017-04-05
PCT/US2018/026134 WO2018187506A1 (en) 2017-04-05 2018-04-04 Ask1 inhibitor compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2020515589A JP2020515589A (ja) 2020-05-28
JP2020515589A5 true JP2020515589A5 (https=) 2021-05-06
JP7196093B2 JP7196093B2 (ja) 2022-12-26

Family

ID=63712299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553366A Active JP7196093B2 (ja) 2017-04-05 2018-04-04 Ask1阻害剤化合物とその使用

Country Status (34)

Country Link
US (3) US20210087167A1 (https=)
EP (1) EP3606519B1 (https=)
JP (1) JP7196093B2 (https=)
KR (1) KR102665145B1 (https=)
CN (1) CN110730661B (https=)
AR (1) AR111407A1 (https=)
AU (1) AU2018250217B2 (https=)
CA (1) CA3059107A1 (https=)
CL (1) CL2019002810A1 (https=)
CO (1) CO2019011708A2 (https=)
CR (1) CR20190503A (https=)
CU (1) CU20190080A7 (https=)
DK (1) DK3606519T3 (https=)
DO (1) DOP2019000255A (https=)
EA (1) EA201992299A1 (https=)
EC (1) ECSP19078393A (https=)
ES (1) ES2992084T3 (https=)
FI (1) FI3606519T3 (https=)
HU (1) HUE068103T2 (https=)
IL (1) IL269711B (https=)
JO (1) JOP20190221A1 (https=)
MA (1) MA49047A (https=)
MX (1) MX394098B (https=)
NI (1) NI201900102A (https=)
NZ (1) NZ758345A (https=)
PE (1) PE20200009A1 (https=)
PH (1) PH12019502288A1 (https=)
PL (1) PL3606519T3 (https=)
PT (1) PT3606519T (https=)
RU (1) RU2019134679A (https=)
SG (1) SG11201909155VA (https=)
SI (1) SI3606519T1 (https=)
TW (1) TWI779022B (https=)
WO (1) WO2018187506A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6754505B2 (ja) * 2017-01-22 2020-09-09 福建広生堂薬業股▲ふん▼有限公司 Ask1阻害剤、その調製方法および使用
AU2018266911C1 (en) 2017-05-12 2022-10-20 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
ES3004523T3 (en) 2018-05-02 2025-03-12 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020006429A1 (en) * 2018-06-28 2020-01-02 Hepatikos Therapeutics, Llc Ask1 isoindolin-1-one inhibitors and methods of use thereof
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
PE20221283A1 (es) 2019-12-27 2022-09-05 Lupin Ltd Compuestos triciclicos sustituidos
PE20230323A1 (es) 2020-05-01 2023-02-22 Pfizer Compuestos de azalactama como inhibidores de hpk1
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
JP7819176B2 (ja) * 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
WO2024020458A1 (en) * 2022-07-20 2024-01-25 Seal Rock Therapeutics, Inc. Method of treating organ diseases or disorders with ask1 inhibitors
TW202547513A (zh) 2024-05-06 2025-12-16 法商Genfit公司 敗血症的治療
WO2026057806A1 (en) 2024-09-13 2026-03-19 Genfit Injectable dosage form of 2-[6-(4-cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
PL2531501T3 (pl) * 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
WO2012079022A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
ES2617339T3 (es) * 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
MX2017003933A (es) * 2014-09-24 2017-06-30 Gilead Sciences Inc Metodos de tratamiento de la enfermedad hepatica.
US10669242B2 (en) 2016-06-10 2020-06-02 Venenum Biodesign, LLC Clostridium difficile toxin inhibitors
WO2018133866A1 (zh) 2017-01-22 2018-07-26 福建广生堂药业股份有限公司 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
JP6754505B2 (ja) * 2017-01-22 2020-09-09 福建広生堂薬業股▲ふん▼有限公司 Ask1阻害剤、その調製方法および使用
EP3580224B1 (en) 2017-02-07 2022-07-13 Biogen MA Inc. Ask1 inhibiting agents
CN109071498B (zh) 2017-02-16 2021-03-30 四川科伦博泰生物医药股份有限公司 激酶抑制剂及其制备方法和用途
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
US11136324B2 (en) 2017-03-03 2021-10-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors
JP2020512976A (ja) 2017-03-27 2020-04-30 ファーマケア,インク. アポトーシスシグナル調節キナーゼ1(ask1)阻害剤化合物
EP3681499A4 (en) * 2017-09-13 2021-04-21 D.E. Shaw Research, LLC CONNECTIONS AS RAS INHIBITORS AND THEIR USE
WO2020006429A1 (en) * 2018-06-28 2020-01-02 Hepatikos Therapeutics, Llc Ask1 isoindolin-1-one inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2020515589A5 (https=)
JP2016516043A5 (https=)
JP2020507589A5 (https=)
JP2017523167A5 (https=)
JP2016525136A5 (https=)
JP2012506870A5 (https=)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
JP2015520769A5 (https=)
JP2016534063A5 (https=)
JP2017505785A5 (https=)
JP2014528464A5 (https=)
JP2017523225A5 (https=)
JP2012505234A5 (https=)
JP2012513416A5 (https=)
JP2017526677A5 (https=)
JP2020523330A5 (https=)
WO2018075959A4 (en) Methods using hdac11 inhibitors
JP2017531678A5 (https=)
JP2019535723A5 (https=)
JP2016540811A5 (https=)
JP2017538767A5 (https=)
JP2010527985A5 (https=)
JP2013544854A5 (https=)
JP2019527724A5 (https=)
JP2024003167A5 (https=)